Hyperphosphatemia Treatment Market Report 2026

Hyperphosphatemia Treatment Market Overview

• Hyperphosphatemia Treatment market size has reached to $5.08 billion in 2025 • Expected to grow to $9.52 billion in 2030 at a compound annual growth rate (CAGR) of 13.4% • Growth Driver: Sustainable Growth Of Hyperphosphatemia Treatment Market Amid Rising Chronic Disease Prevalence • Market Trend: Increasing Focus On Product Development To Provide Reliable Services To Their Customers • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hyperphosphatemia Treatment Market?

Hyperphosphatemia treatment refers to a class of drugs that boost renal excretion to treat patients' hyperphosphatemia. The most efficient way to do this is through volume replenishment with saline and forced diuresis with a loop diuretic such as furosemide or bumetanide. The main products in the hyperphosphatemia treatment market are sevelamer, calcium-based phosphate binders, iron-based phosphate binders, lanthanum carbonate, and others. The sevelamer market consists of sales of sevelamer products by entities (organizations, partnerships, and sole traders) that refer to phosphate binding medication used for the treatment of hyperphosphatemia in patients with chronic and kidney diseases. The hyperphosphatemia treatment is distributed through hospital pharmacies, retail pharmacies, and online stores. By dosage form, it is segmented into capsules, tablets, and syrups.

What Is The Hyperphosphatemia Treatment Market Growth Forecast?

The hyperphosphatemia treatment market size is expected to see rapid growth in the next few years. It will grow to $9.52 billion in 2030 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to advancements in non-calcium phosphate binders, integration of digital health monitoring, rise in precision medicine adoption, increasing investment in novel therapies, expansion of e-pharmacy channels. Major trends in the forecast period include rising prevalence of chronic kidney disease, increasing adoption of phosphate binders, growth of home-based dialysis treatments, expansion of hospital pharmacy networks, development of novel hyperphosphatemia therapies.

What Is The Driver Of The Hyperphosphatemia Treatment Market?

The increase in chronic diseases among patients is driving the growth of the hyperphosphatemia treatment market. Chronic diseases are non-communicable and require long-term care. A vast majority of chronic diseases can be categorized as cardiovascular diseases, chronic kidney disease, chronic respiratory conditions, hyperparathyroidism, diabetes, and cancer. For instance, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 41 million deaths, which is 74% of those caused by non-communicable diseases (NCDs) or chronic diseases every year globally. Furthermore, in February 2023, according to SingleCare Services LLC, a US-based healthcare savings platform, the prevalence of kidney diseases is increasing, and each year untreated kidney failure claims the lives of approximately 1 million individuals. There has been an increase in hyperphosphatemia among patients with end-stage renal disease (ESRD), thus contributing to an increase in demand for hyperphosphatemia treatment or drugs.

Key Players In The Global Hyperphosphatemia Treatment Market

Major companies operating in the hyperphosphatemia treatment market are Sanofi SA, Akebia Therapeutics Inc., Ardelyx Inc., Astellas Pharma Inc., Fresenius Medical Care AG & Co. KGaA, Lupin Limited, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Ultragenyx Pharmaceutical Inc., Unicycive Therapeutics Inc., Vifor Pharma Management Ltd., Zeria Pharmaceutical Co. Ltd., Amgen Inc., AstraZeneca plc, Baxter International Inc., Kyowa Kirin Co. Ltd., Ipsen, Shionogi & Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Bayer AG, Boehringer Ingelheim International GmbH, Novartis International AG

Global Hyperphosphatemia Treatment Market Trends and Insights

Major companies operating in the hyperphosphatemia treatment market are focusing on innovative product development, such as Xphozah, to drive revenues in their market. Xphozah is designed to treat hyperphosphatemia, characterized by excessive phosphorus, causing calcium removal from bones and various body parts. For instance, in October 2023, Ardelyx Inc., a US-based biopharmaceutical company, got approval for Xphozah. This was approved to treat hyperphosphatemia, which removes calcium from bones and other body parts. Excess phosphorus can result in brittle bones, joint pain, cramping muscles, and itchy skin. The medication has been approved by the FDA for use in patients who have not responded well to phosphate binder therapies, which are the condition's current standard of care, or who are intolerant to them.

What Are Latest Mergers And Acquisitions In The Hyperphosphatemia Treatment Market?

In May 2023, Life Healthcare Group Holdings Limited, a South Africa-based healthcare services group, acquired Fresenius Medical Care AG and Co. KGaA for an undisclosed amount. This acquisition would enhance Life Healthcare’s acute and ongoing renal dialysis treatments offered in South Africa. With this acquisition, Life Healthcare has committed to playing a crucial role in ensuring the continuity of their current patient care plans. Fresenius Medical Care AG and Co. KGaA is a Germany-based company that manufactures drugs for hyperphosphatemia treatment.

What Defines the Hyperphosphatemia Treatment Market?

The hyperphosphatemia treatment market includes revenues earned by lowering the phosphate load and maintaining serum phosphorus levels within the normal range. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hyperphosphatemia Treatment Market Report 2026?

The hyperphosphatemia treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hyperphosphatemia treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.